1. Home
  2. SNES vs GNPX Comparison

SNES vs GNPX Comparison

Compare SNES & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SenesTech Inc.

SNES

SenesTech Inc.

N/A

Current Price

$1.50

Market Cap

12.1M

Sector

Industrials

ML Signal

N/A

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.92

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNES
GNPX
Founded
2004
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1M
11.8M
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
SNES
GNPX
Price
$1.50
$0.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.3K
771.7K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
77.99
N/A
EPS
N/A
N/A
Revenue
$600,000.00
N/A
Revenue This Year
$29.00
N/A
Revenue Next Year
$95.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
132.56
N/A
52 Week Low
$1.41
$0.14
52 Week High
$5.99
$12.97

Technical Indicators

Market Signals
Indicator
SNES
GNPX
Relative Strength Index (RSI) 42.95 30.17
Support Level N/A $0.15
Resistance Level $1.75 $2.12
Average True Range (ATR) 0.08 0.10
MACD 0.01 0.01
Stochastic Oscillator 38.46 16.33

Price Performance

Historical Comparison
SNES
GNPX

About SNES SenesTech Inc.

SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

Share on Social Networks: